KING'S COLLEGE LONDON
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Colleges, Universities, and Professional Schools, Commercial Economic, Sociological, and Educational Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about KING'S COLLEGE LONDON
Live alerts from global media, monitored by Business Radar
2023-10-24 (yahoo.com)
Neurocentrx Reports Positive Top-line Results from Phase 1 Clinical Study of its Lead Oral Ketamine Capsule Programme
EDINBURGH, Scotland, October 24, 2023 -- Neurocentrx, a biopharmaceutical company focused on the development of oral ketamine for the treatment of mood disorders and other indications, today announced positive topline results from its Phase1 clinical study of KET-IR, its novel oral ketamine
Read more
(itnewsonline.com)
2U Reports Results for Third Quarter 2023
2U Reports Results for Third Quarter 2023
Read more